CA3074581A1 - Method for producing influenza ha split vaccine - Google Patents
Method for producing influenza ha split vaccine Download PDFInfo
- Publication number
- CA3074581A1 CA3074581A1 CA3074581A CA3074581A CA3074581A1 CA 3074581 A1 CA3074581 A1 CA 3074581A1 CA 3074581 A CA3074581 A CA 3074581A CA 3074581 A CA3074581 A CA 3074581A CA 3074581 A1 CA3074581 A1 CA 3074581A1
- Authority
- CA
- Canada
- Prior art keywords
- influenza
- split vaccine
- vaccine
- lah
- split
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/11—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Mycology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017169230 | 2017-09-04 | ||
| JP2017-169230 | 2017-09-04 | ||
| JP2018-137952 | 2018-07-23 | ||
| JP2018137952A JP7403733B2 (ja) | 2017-09-04 | 2018-07-23 | インフルエンザｈａスプリットワクチンの製造方法 |
| PCT/JP2018/032537 WO2019045090A1 (ja) | 2017-09-04 | 2018-09-03 | インフルエンザｈａスプリットワクチンの製造方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3074581A1 true CA3074581A1 (en) | 2019-03-07 |
Family
ID=65815411
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3074581A Pending CA3074581A1 (en) | 2017-09-04 | 2018-09-03 | Method for producing influenza ha split vaccine |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11732031B2 (https=) |
| EP (1) | EP3679948A4 (https=) |
| JP (1) | JP7403733B2 (https=) |
| KR (1) | KR102733152B1 (https=) |
| CN (1) | CN111372605B (https=) |
| AU (1) | AU2018325899B2 (https=) |
| CA (1) | CA3074581A1 (https=) |
| EA (1) | EA202090587A1 (https=) |
| PH (1) | PH12020500414A1 (https=) |
| SG (1) | SG11202001937TA (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7403733B2 (ja) | 2017-09-04 | 2023-12-25 | 国立感染症研究所長 | インフルエンザｈａスプリットワクチンの製造方法 |
| CA3107409A1 (en) | 2018-07-23 | 2020-01-30 | Japan As Represented By Director General Of National Institute Of Infectious Diseases | Composition containing influenza vaccine |
| EA202192398A1 (ru) | 2019-03-04 | 2021-11-23 | Джэпэн Эз Репризентид Баи Директор Дженерал Оф Нэшнл Инститьют Оф Инфекшес Дизизис | Способ приготовления сплит-вакцины против гриппа на основе гемагглютинина |
| KR20220098370A (ko) * | 2019-11-07 | 2022-07-12 | 세퀴러스 유케이 리미티드 | 감소된 입자 크기를 가지는 바이러스 백신을 제조하기 위한 조성물 및 방법 |
| CN121816361A (zh) | 2023-04-26 | 2026-04-07 | 国立健康危机管理研究机构 | 抗流感抗体 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8278083B2 (en) | 2004-03-22 | 2012-10-02 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Inactivated influenza virus compositions |
| JPWO2008114819A1 (ja) | 2007-03-20 | 2010-07-08 | 大日本住友製薬株式会社 | 新規アデニン化合物 |
| CA2731686C (en) | 2008-07-25 | 2020-04-07 | Institute For Research In Biomedicine | Neutralizing anti-influenza a virus antibodies and uses thereof |
| WO2010047509A2 (ko) | 2008-10-24 | 2010-04-29 | 아주대학교 산학협력단 | 친화도와 안정성이 향상된 항 ｄｒ5 항체, 및 이를 포함하는 암 예방 또는 치료용 조성물 |
| CN101524538A (zh) * | 2009-03-26 | 2009-09-09 | 成都康华生物制品有限公司 | 一种流感-大流行流感二价联合疫苗及其制备方法 |
| EP3098236A1 (en) | 2010-03-08 | 2016-11-30 | Celltrion, Inc. | Human monoclonal antibodies derived from human b cells and having neutralizing activity against influenza a viruses |
| CN102939103A (zh) | 2010-03-30 | 2013-02-20 | 西奈山医学院 | 流感病毒疫苗及其应用 |
| BR112013025254A2 (pt) | 2011-04-21 | 2016-09-06 | Baxter Internat Inc E Baxter Healthcare S A | método para isolar um antígeno de uma composição de vacina |
| WO2013173256A2 (en) | 2012-05-16 | 2013-11-21 | Kj Biosciences, Llc | New and improved influenza vaccines |
| KR20140118682A (ko) | 2013-03-29 | 2014-10-08 | (주)셀트리온 | 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물 |
| AU2015305690A1 (en) | 2014-08-18 | 2017-03-02 | Sanofi Pasteur Inc. | Alkylated influenza vaccines |
| US11191727B2 (en) | 2014-12-31 | 2021-12-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Multivalent nanoparticle-based vaccines |
| JP7403733B2 (ja) | 2017-09-04 | 2023-12-25 | 国立感染症研究所長 | インフルエンザｈａスプリットワクチンの製造方法 |
| CA3107409A1 (en) | 2018-07-23 | 2020-01-30 | Japan As Represented By Director General Of National Institute Of Infectious Diseases | Composition containing influenza vaccine |
-
2018
- 2018-07-23 JP JP2018137952A patent/JP7403733B2/ja active Active
- 2018-09-03 EA EA202090587A patent/EA202090587A1/ru unknown
- 2018-09-03 AU AU2018325899A patent/AU2018325899B2/en active Active
- 2018-09-03 SG SG11202001937TA patent/SG11202001937TA/en unknown
- 2018-09-03 KR KR1020207009033A patent/KR102733152B1/ko active Active
- 2018-09-03 CA CA3074581A patent/CA3074581A1/en active Pending
- 2018-09-03 EP EP18852584.4A patent/EP3679948A4/en active Pending
- 2018-09-03 CN CN201880070955.0A patent/CN111372605B/zh active Active
-
2019
- 2019-03-04 US US16/292,065 patent/US11732031B2/en active Active
-
2020
- 2020-03-02 PH PH12020500414A patent/PH12020500414A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA202090587A1 (ru) | 2020-08-24 |
| AU2018325899B2 (en) | 2023-04-20 |
| KR102733152B1 (ko) | 2024-11-21 |
| EP3679948A1 (en) | 2020-07-15 |
| CN111372605A (zh) | 2020-07-03 |
| EP3679948A4 (en) | 2021-04-28 |
| AU2018325899A1 (en) | 2020-04-09 |
| CN111372605B (zh) | 2024-12-17 |
| JP2019043937A (ja) | 2019-03-22 |
| JP7403733B2 (ja) | 2023-12-25 |
| KR20200047629A (ko) | 2020-05-07 |
| US20190345231A1 (en) | 2019-11-14 |
| PH12020500414A1 (en) | 2021-03-08 |
| SG11202001937TA (en) | 2020-04-29 |
| US11732031B2 (en) | 2023-08-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11732031B2 (en) | Method for producing influenza HA split vaccine | |
| US10087218B2 (en) | Vaccine antigens that direct immunity to conserved epitopes | |
| US4625015A (en) | Broad spectrum influenza antisera | |
| US20230406910A1 (en) | Method for producing influenza ha split vaccine | |
| AU2020233456B2 (en) | Method for preparing influenza HA split vaccine | |
| US8883165B2 (en) | Modified peptide vaccine derived from influenza M2 | |
| JP7203015B2 (ja) | 免疫原性組成物 | |
| WO2009152518A1 (en) | Novel peptide adjuvant for influenza vaccination | |
| HK40032891A (en) | Method for producing influenza ha split vaccine | |
| TWI857017B (zh) | 流感ha裂解疫苗之製造方法 | |
| EA045852B1 (ru) | Способ получения сплит-вакцины с ha гриппа | |
| EA045912B1 (ru) | Способ приготовления сплит-вакцины на основе гемагглютинина гриппа | |
| US20120156242A1 (en) | An Antigenic Peptide Derived From Influenza Virus And A Method For Selecting Anti-Influenza Virus Antibody | |
| HK40068192A (en) | Method for preparing influenza ha split vaccine | |
| JP2023515829A (ja) | 小児対象のための高用量インフルエンザワクチン |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230901 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240829 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240829 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240829 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250523 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250722 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250722 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250923 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251126 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251126 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251126 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20260409 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260409 |